Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Predicting Hyperhomocysteinemia by Methylenetetrahydrofolate Reductase C677T Polymorphism in Chinese Patients With

Yu Wang1, Xin Xu1, Yong Huo2

  • 1Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, P. R. China.

Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
|January 25, 2014
PubMed

Insights

The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is a useful predictor of hyperhomocysteinemia (HHcy) in Chinese hypertensive patients. The TT genotype strongly correlates with HHcy, especially severe forms, aiding in screening.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Disease Research
  • Nutritional Biochemistry

Background:

  • Hypertension is a major cardiovascular risk factor.
  • Hyperhomocysteinemia (HHcy) is linked to increased cardiovascular risk.
  • The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is implicated in homocysteine metabolism.

Purpose of the Study:

  • To assess the MTHFR C677T polymorphism's efficacy in predicting HHcy among Chinese patients with hypertension.
  • To determine the association between MTHFR C677T genotype and plasma total homocysteine (tHcy) levels.

Main Methods:

  • Meta-analysis of 4 previous studies involving 1058 Chinese hypertensive patients.
  • Measurement of plasma tHcy levels and C677T genotyping.
  • Logistic regression models and receiver-operating characteristic (ROC) curve analysis to evaluate predictive performance.

Main Results:

  • The TT genotype of MTHFR C677T polymorphism was consistently associated with elevated tHcy levels (51% increase overall).
  • The TT genotype significantly increased the odds ratio for HHcy, particularly for severe forms (OR=17.9).
  • Predictive performance improved with HHcy severity, with sensitivity reaching 70.3% for severe HHcy.

Conclusions:

  • The MTHFR C677T polymorphism demonstrates good sensitivity and moderate specificity for screening severe HHcy in hypertensive Chinese patients.
  • Incorporating age and gender further enhances the predictive accuracy, especially for milder forms of HHcy.
Abstract

Keywords:
MTHFRhyperhomocysteinemiahypertensionpolymorphismprediction

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121